Glucose lowering agents with proven cardiovascular benefits and weight-loss effects, such as sodium-glucose cotransporter 2 inhibitors (SGLT2i) and GLP1-RA, should be preferred primarily in diabetic PsA cases [131]. The gene discussed is GLP1R; the disease is rheumatoid arthritis.